Anabolic steroids can cause liver injury, especially impaired bile flow called cholestasis. Yellow eyes or skin, dark urine and persistent itching deserve medical assessment even when liver enzyme results look only mildly abnormal. Other reported injuries include changes in liver blood vessels and liver growths. A product name, route of use or a normal blood panel cannot establish that continued use is safe.
Different liver findings need different assessment
Liver injury is not one condition. An enzyme rise, blocked bile flow and a structural lesion have different implications. The table identifies reported patterns rather than predicting which one a person has.
| Reported pattern | What it means | A limit to remember |
|---|---|---|
| Enzyme elevations during AAS exposure | Blood markers are above their reference range. | Exercise and other illnesses can contribute; the number alone does not identify the cause. |
| Anabolic steroid cholestasis | Bile handling is impaired, often causing jaundice and itching. | Marked symptoms can coexist with modest enzyme changes. |
| Peliosis and nodular changes | Abnormal blood spaces or changes in liver tissue structure. | Routine enzymes may not reveal the lesion. |
| Adenoma or liver cancer | Benign or malignant growths reported with androgen exposure. | Rare reports do not provide a precise risk for an individual user. |
A 2024 clinical review of anabolic steroid liver injury describes this range. Much of the clinical evidence comes from selected patients who became ill. It cannot tell us what percentage of everyone taking an unverified product will develop each problem.
Steroid chemistry, oral products and injections
Some steroids have a chemical modification called 17 alpha alkylation. It slows their breakdown in the liver and permits oral activity, but is closely associated with cholestatic injury. Examples include oxymetholone, stanozolol and methyltestosterone. LiverTox’s androgenic steroid record distinguishes these compounds from testosterone esters. The words oral and injectable do not describe this chemical difference.
Not every oral androgen has the same structure. An injection is not a guarantee against liver injury, and switching a suspected harmful product to another route is not treatment. The oral steroid liver risk page covers the formulation question. Recognising injury and getting care takes priority over choosing another formulation.
The current US XYOSTED testosterone enanthate label discusses serious hepatic effects associated with certain androgens and tells patients to report signs of liver dysfunction. It is a named prescription product label, not reassurance about another vial, an unknown ingredient or a nonmedical combination.
Cholestasis can persist despite modest enzyme results
Cholestasis means bile flow is impaired. It may cause itching, fatigue, nausea, dark urine and jaundice. LiverTox describes onset after weeks or months, sometimes later, and symptoms that may persist after exposure ends. ALT and alkaline phosphatase can be modestly raised or occasionally normal despite substantial jaundice. The term bland cholestasis refers to limited inflammation on a biopsy; it does not mean the illness feels mild or needs no treatment.
In a 2019 Drug Induced Liver Injury Network study, 44 men with liver injury linked to bodybuilding supplements all had jaundice; 84% reported itching and 71% were hospitalised. None died or required a transplant in that series. Some analysed products contained anabolic steroids absent from their labels. These were enrolled injury cases with probable or stronger attribution, not a representative sample of supplement users.
The same study found that an early enzyme ratio could classify some cases as hepatocellular injury even while their symptoms showed cholestasis. A calculated pattern can change over time. It is not a severity score, and it should not override visible jaundice or a worsening clinical condition.
Rare structural injuries are a separate concern
Peliosis hepatis involves abnormal spaces containing blood within the liver. It can be silent or present with discomfort, and rupture can cause internal bleeding. Androgen exposure has also been associated with nodular tissue changes. These are different from an isolated ALT rise and require assessment suited to the suspected lesion.
A hepatic adenoma is a benign liver growth, but benign does not mean it can never bleed or develop malignant changes. AASLD’s explanation of hepatic adenomas lists anabolic androgenic steroid exposure among risk factors and notes that blood tests are often normal. Imaging and specialist interpretation are needed to distinguish an adenoma from other masses. Reports of hepatocellular carcinoma also exist with prolonged androgen exposure, but do not establish a universal timeline or personal cancer probability.
Do not interpret abdominal discomfort as proof of a tumour. Equally, a recent normal enzyme panel does not rule out a structural problem. Sudden or severe abdominal pain needs urgent emergency assessment, as described below.
What liver tests can and cannot show
ALT and AST reflect cell injury, not a direct percentage of liver function. Alkaline phosphatase, or ALP, can come from the liver or bone. GGT can help identify a hepatic source of an ALP rise. Bilirubin describes pigment handling, while albumin and clotting tests add information about protein production and other influences. AASLD’s 2025 approach to abnormal liver enzymes explains these distinctions.
PT and INR are clotting measurements. An abnormal result can reflect liver dysfunction, vitamin K deficiency or medicines such as anticoagulants; it needs interpretation. A low albumin can also have causes outside the liver. Reading one value without the rest of the panel, symptoms and prior results can mislead.
In a small exercise study published in 2008, 15 healthy men unaccustomed to weightlifting performed a one hour session. AST, ALT and muscle markers rose and remained increased for at least seven days, while bilirubin, GGT and ALP stayed within range. This demonstrates a possible exercise effect; it does not prove that a particular steroid user’s abnormal result is muscular rather than hepatic.
Tell the clinician about recent training and muscle pain. Follow any testing preparation instructions, but do not delay assessment of jaundice or serious symptoms to wait for exercise effects to settle. The liver blood test page covers marker interpretation in more detail. Keep dated results so the clinical team can review the trend.
How clinicians investigate a suspected drug injury
Drug induced liver injury, often shortened to DILI, is assessed by combining the history, test pattern, timing and exclusion of other causes. There is no single blood test that proves a particular steroid caused it. AASLD’s drug and supplement injury recommendations stress the difficulty of distinguishing DILI from competing explanations.
A clinician may assess viral hepatitis, alcohol related illness, metabolic liver disease, autoimmune disease and obstruction of the bile ducts. Ultrasound may help investigate a blockage; other imaging or a liver biopsy is selected for unresolved questions. Not every patient needs a biopsy, and a liver injury label should not end the search for another treatable cause.
Jaundice can also result from increased breakdown of red blood cells or problems outside the liver. Healthdirect’s adult jaundice information describes the different pathways and the use of blood tests, examination and imaging. Symptoms during pregnancy need immediate clinical review. Tell the team about pregnancy, previous liver disease, infection exposures and all current medicines.
Other products can add harm or obscure the cause
Give the clinician the entire exposure history: prescribed drugs, anabolic steroids, selective androgen receptor modulators (SARMs), alcohol, recreational substances, herbal preparations and bodybuilding supplements. A label does not verify what is inside. The FDA warns about hidden steroid ingredients and false liver protection claims in some bodybuilding products. Adding a product sold as liver support can introduce another unknown exposure.
A 2024 Australian hospital series included 23 patients exposed to AAS, SARMs, bodybuilding supplements or combinations. Seventeen were admitted and one patient using a combination required transplantation. Attribution was uncertain in many cases. This mixed series cannot supply a transplant rate for AAS alone or prove that a SARM is a safer alternative.
Acetaminophen, called paracetamol in the UK and Australia, appears in many pain and cold medicines. Taking several products can duplicate the ingredient. The FDA’s acetaminophen advice addresses serious liver injury from excessive use. If an overdose may have occurred, seek emergency medical advice immediately, even without symptoms. Follow NHS poisoning advice: bring the packaging and do not induce vomiting. Read more about the separate overlap with alcohol on the steroids and alcohol page.
When symptoms need attention
Care, stopping exposure and recovery
Removing the suspected offending androgen is central to management of diagnosed androgen related liver injury. Reducing the dose or changing the route is not a substitute. Contact the treating clinician urgently about the next dose of a prescribed product when symptoms suggest injury; follow its specific instructions. Medical support can also address withdrawal from nonmedical exposure.
Treatment may involve relief of itching, nutrition support and monitoring of bilirubin, clotting and kidney function. Evidence that ursodiol or corticosteroids reliably shorten AAS cholestasis is limited. Reports of improvement after a treatment do not establish that it caused recovery. A specialist selects treatment for the diagnosis; do not start a home drug or supplement protocol.
Recovery can take months. Among the 20 patients with documented normalisation in the Australian mixed exposure series, the median time to normal liver biochemistry was 175 days from presentation, with substantial variation. That is not a deadline for an individual or a duration specific to AAS alone. Symptoms, bilirubin and enzymes may improve at different rates. Ongoing or worsening symptoms require review even after exposure stops.
Severe cholestasis can be complicated by kidney injury. A published case of bile acid nephropathy illustrates that connection; it does not mean everyone with jaundice will develop kidney failure. See the kidney health page for renal symptoms and test limits. Structural liver lesions require their own follow up rather than reassurance from a falling ALT.
What to bring to the appointment
- All product names, ingredient lists, photographs of packaging and prescription details.
- Dates started and stopped, amounts used, routes, combinations and any recent change in product.
- A symptom timeline, including itching, urine or stool changes, jaundice, appetite, weight loss and pain.
- Dated blood results, previous liver diagnoses, alcohol use and recent illness or training.
- A question list: which results need urgent action, when to repeat tests, who reviews them and what to do if symptoms worsen.
Do not restart a suspected product to test if symptoms return. LiverTox’s account of drug injury assessment cautions against deliberate reexposure. Ask the clinical team to document the suspected exposure and the plan for follow up. Use the appointment preparation page to organise the information. A complete history helps care even when the exact ingredient or cause remains uncertain.